Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Probuphine vs Sublingual Buprenorphine in Opioid Dependence
NCT00768482Phase 3Terminated
- Sponsor
- Titan Pharmaceuticals, Inc.
- Start
- Sep 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of buprenorphine implant in opioid use disorder (OUD), sponsored by Titan Pharmaceuticals, Inc. Primary endpoint: Plasma Buprenorphine Area Under the Curve from 0 to 24 hours. Started Sep 2008; status: terminated.
02
Drugs
buprenorphine implant
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00768482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768482.